GSK Acquires Syndivia's Prostate Cancer ADC for £268m
GSK has acquired the rights to Syndivia's preclinical antibody drug conjugate (ADC) for prostate cancer treatment.
Despite having its own ADC in development for prostate cancer, GSK is investing in another ADC, fuelling industry buzz for the anti-tumour modality.
The gold standard of business intelligence.
GSK's move combines business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Author's summary: GSK buys Syndivia's ADC for £268m.
More News
- Regional Educator Network shows off programs in Pendleton - East Oregonian
- Commentary: From Latter-day Saint to Catholic saint? The incredible spiritual journey of a mystical Utah native.
- Australian government bans Dutch volleyball rapist
- Feature Grade Blackbutt from Big River Group | ArchitectureAu
- Australian government bans Dutch volleyball rapist